Gf Fund Management Co. Ltd. Trevi Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,968 shares of TRVI stock, worth $11,729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,968
Previous 1,614
21.93%
Holding current value
$11,729
Previous $6.65 Million
86.15%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$67.8 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$61.1 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$27 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$22.9 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$20.8 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $348M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...